CZ289925B6 - Derivát pyrrolo[3,4-d]pyrimidinonu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití - Google Patents

Derivát pyrrolo[3,4-d]pyrimidinonu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití Download PDF

Info

Publication number
CZ289925B6
CZ289925B6 CZ19992204A CZ220499A CZ289925B6 CZ 289925 B6 CZ289925 B6 CZ 289925B6 CZ 19992204 A CZ19992204 A CZ 19992204A CZ 220499 A CZ220499 A CZ 220499A CZ 289925 B6 CZ289925 B6 CZ 289925B6
Authority
CZ
Czechia
Prior art keywords
pyrrolo
formula
methyl
naphthalenylmethyl
methylpropyl
Prior art date
Application number
CZ19992204A
Other languages
Czech (cs)
English (en)
Other versions
CZ220499A3 (cs
Inventor
Martin Cooper
David Cheshire
David Donald
Mark Furber
Matthew Perry
Richard Harrison
Nicholas Tomkinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CZ220499A3 publication Critical patent/CZ220499A3/cs
Publication of CZ289925B6 publication Critical patent/CZ289925B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CZ19992204A 1996-12-21 1997-12-18 Derivát pyrrolo[3,4-d]pyrimidinonu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití CZ289925B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds

Publications (2)

Publication Number Publication Date
CZ220499A3 CZ220499A3 (cs) 2000-02-16
CZ289925B6 true CZ289925B6 (cs) 2002-04-17

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19992204A CZ289925B6 (cs) 1996-12-21 1997-12-18 Derivát pyrrolo[3,4-d]pyrimidinonu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití

Country Status (23)

Country Link
US (8) US6046204A (xx)
EP (1) EP0946562B1 (xx)
JP (1) JP2001507687A (xx)
KR (1) KR20000069605A (xx)
CN (1) CN1246119A (xx)
AT (1) ATE215088T1 (xx)
AU (1) AU717429B2 (xx)
BR (1) BR9714063A (xx)
CA (1) CA2275312A1 (xx)
CZ (1) CZ289925B6 (xx)
DE (1) DE69711430T2 (xx)
EE (1) EE9900315A (xx)
GB (1) GB9626643D0 (xx)
HU (1) HUP0002839A3 (xx)
ID (1) ID21682A (xx)
IL (1) IL130538A0 (xx)
IS (1) IS5082A (xx)
NO (1) NO993027L (xx)
NZ (1) NZ336124A (xx)
PL (1) PL334228A1 (xx)
SK (1) SK76699A3 (xx)
TR (1) TR199901433T2 (xx)
WO (1) WO1998028301A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
PT1147087E (pt) 1999-01-15 2005-09-30 Altana Pharma Ag Feantridina-n-oxidos com actividade de inibicao de pde-iv
WO2000042018A1 (en) 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
CA2359449A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Phenanthridine-n-oxides with pde-iv inhibiting activity
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
JP5140225B2 (ja) * 2000-08-14 2013-02-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
TW200407315A (en) * 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
CA2533534C (en) * 2003-07-24 2013-03-19 Tecomet, Inc. Assembled non-random foams
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
SI2024367T1 (sl) 2006-05-04 2011-04-29 Pulmagen Therapeutics Inflammation Ltd Tetrahidropirolopirimidinedioni in njihova uporaba kot äśloveĺ ki neutrofil elastazni inhibitorji
WO2007143705A2 (en) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
JP5701608B2 (ja) 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
MX2011005935A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP5710493B2 (ja) 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2011019737A1 (en) * 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN108129486B (zh) * 2018-01-25 2020-06-05 华东理工大学 嘧啶酮衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Also Published As

Publication number Publication date
WO1998028301A1 (en) 1998-07-02
EE9900315A (et) 2000-02-15
GB9626643D0 (en) 1997-02-12
CN1246119A (zh) 2000-03-01
NO993027D0 (no) 1999-06-18
KR20000069605A (ko) 2000-11-25
US6046204A (en) 2000-04-04
BR9714063A (pt) 2002-01-02
AU5580998A (en) 1998-07-17
ID21682A (id) 1999-07-08
US6306863B1 (en) 2001-10-23
SK76699A3 (en) 2000-05-16
DE69711430T2 (de) 2002-10-31
DE69711430D1 (de) 2002-05-02
AU717429B2 (en) 2000-03-23
CZ220499A3 (cs) 2000-02-16
PL334228A1 (en) 2000-02-14
EP0946562B1 (en) 2002-03-27
US20020025966A1 (en) 2002-02-28
US6136974A (en) 2000-10-24
HUP0002839A3 (en) 2001-04-28
ATE215088T1 (de) 2002-04-15
JP2001507687A (ja) 2001-06-12
EP0946562A1 (en) 1999-10-06
IL130538A0 (en) 2000-06-01
US6229013B1 (en) 2001-05-08
CA2275312A1 (en) 1998-07-02
US6166206A (en) 2000-12-26
NZ336124A (en) 2001-03-30
NO993027L (no) 1999-08-20
HUP0002839A2 (hu) 2001-02-28
US6211368B1 (en) 2001-04-03
US20030162798A1 (en) 2003-08-28
IS5082A (is) 1999-06-14
TR199901433T2 (xx) 1999-09-21

Similar Documents

Publication Publication Date Title
CZ289925B6 (cs) Derivát pyrrolo[3,4-d]pyrimidinonu, způsob jeho přípravy, farmaceutický prostředek s jeho obsahem a jeho pouľití
EP1226144B1 (en) Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
EP0975636B1 (en) 1h-pyrazolo[3,4-d]pyrimidine-4,6-diones as t-cell proliferation inhibitors
US20120302608A1 (en) Novel Imidazole Derivatives Useful for the Treatment of Arthritis
US5416211A (en) Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
JP2009502734A (ja) Ｌｃｋ阻害剤としての縮合複素環
US5663339A (en) Process for preparing 5-substituted pyrrolo-[2,3-D] pyrimidines
JP2004091369A (ja) 新規ビフェニル化合物
US5281708A (en) 9-Substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors of PNP
MXPA99005779A (en) Pyrrolo[3,4-d
CZ360599A3 (cs) Nové sloučeniny
JP4028236B6 (ja) ｐ３８プロテインキナーゼのインヒビターとしてのアルキルアミノ置換二環式窒素複素環
CN116063325A (zh) 具有btk调节作用的大环化合物及其用途
CZ158097A3 (en) PROCESS FOR PREPARING A DERIVATIVE OF PYRROLO£2,3/d|PYRIMIDINE BEING SUBSTITUTED IN POSITION 5

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 19971218